InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Jyong Biotech Ltd.

MENS Clue Score26
Cayman Islands CIK 0001954488
$2.10 +0.00% Close, 12 Oct 2026
Alert on the numbers Alert on insider trades
Price $2.10 −96.23% Close, 12 Oct 2026

Closing prices at the end of each trading day, from 17 Jun 2025. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2023Operating income−2.8Net income−4.4EPS, diluted−0.06Fiscal year 2024Operating income−2.1Net income−3.0EPS, diluted−0.04Fiscal year 2025Operating income−2.6Net income−4.7EPS, diluted−0.06
FY2023FY2024FY2025
Operating income −2.8 −2.1 −2.6
Net income −4.4 −3.0 −4.7
Growth
EPS, diluted −0.06 −0.04 −0.06
Growth

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2023Operating cash flow−2.6Fiscal year 2024Operating cash flow−3.6Fiscal year 2025Operating cash flow−3.0
FY2023FY2024FY2025
Operating cash flow −2.6 −3.6 −3.0

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2023Cash1.7Shareholders’ equity−34.1Fiscal year 2024Cash0.1Shareholders’ equity−36.5Fiscal year 2025Cash1.2Total debt2.1Net cash (debt)−0.9Shareholders’ equity−24.9
FY2023FY2024FY2025
Cash 1.7 0.1 1.2
Total debt n/a n/a 2.1
Net cash (debt) n/a n/a −0.9
Shareholders’ equity −34.1 −36.5 −24.9

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Cash flow

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Operations
−2.6 −3.6 −3.0
Growth
Investment
0.1 n/a −13.5
Financing
2.0 2.0 17.6

Capital expenditure, dividends and buybacks are shown as money out, so negative.